Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shibani Nicum

Showing results (1-10 of 41) with videos related to

Pageof 5
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 31, 2022
PARPs: All for One and One for All? Enhancing Diversity in Clinical TrialsShibani Nicum, Sarah P Blagden
Lancet (London, England)|January 24, 2021
A source of hope for platinum-resistant ovarian cancer?Sarah P Blagden, Shibani Nicum
Acta Oncologica (Stockholm, Sweden)|August 6, 2003
Colorectal cancerShibani Nicum, Rachel Midgley, David J Kerr
BJOG : an International Journal of Obstetrics and Gynaecology|February 9, 2026
Risk of Cancer With Hormone Replacement Therapy: A Narrative ReviewGabriella Yongue, Zachary Nash, Vikram Talaulikar, et al.
Journal of Medical Case Reports|April 30, 2008
Malignant mesothelioma with unexpected contralateral mediastinal shift: a case reportJames S Myerson, Shibani Nicum, Bhupinder Sharma, et al.
Gynecologic Oncology|February 8, 2024
A systematic review of ethnic minority participation in randomised controlled trials of systemic therapies for gynecological cancersLuke Steventon, Shibani Nicum, Kenneth Man, et al.
The Cochrane Database of Systematic Reviews|October 7, 2011
Epidermal growth factor receptor blockers for the treatment of ovarian cancerKrishnayan Haldar, Kezia Gaitskell, Andrew Bryant, et al.
The Cochrane Database of Systematic Reviews|September 9, 2011
Angiogenesis inhibitors for the treatment of ovarian cancerKezia Gaitskell, Igor Martinek, Andrew Bryant, et al.
The Cochrane Database of Systematic Reviews|June 18, 2010
DNA-repair pathway inhibitors for the treatment of ovarian cancerIgor Martinek, Krishnayan Haldar, Kezia Gaitskell, et al.
BMJ Open|January 16, 2021
Randomised phase II trial of olaparib, chemotherapy or olaparib and cediranib in patients with platinum-resistant ovarian cancer (OCTOVA): a study protocolAnita Mansouri, Naomi McGregor, Rachel Dunn, et al.
Pageof 5

Showing results (1-10 of 41) with videos related to

Sort By:
Pageof 5
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 31, 2022
PARPs: All for One and One for All? Enhancing Diversity in Clinical TrialsShibani Nicum, Sarah P Blagden
Lancet (London, England)|January 24, 2021
A source of hope for platinum-resistant ovarian cancer?Sarah P Blagden, Shibani Nicum
Acta Oncologica (Stockholm, Sweden)|August 6, 2003
Colorectal cancerShibani Nicum, Rachel Midgley, David J Kerr
BJOG : an International Journal of Obstetrics and Gynaecology|February 9, 2026
Risk of Cancer With Hormone Replacement Therapy: A Narrative ReviewGabriella Yongue, Zachary Nash, Vikram Talaulikar, et al.
Journal of Medical Case Reports|April 30, 2008
Malignant mesothelioma with unexpected contralateral mediastinal shift: a case reportJames S Myerson, Shibani Nicum, Bhupinder Sharma, et al.
Gynecologic Oncology|February 8, 2024
A systematic review of ethnic minority participation in randomised controlled trials of systemic therapies for gynecological cancersLuke Steventon, Shibani Nicum, Kenneth Man, et al.
The Cochrane Database of Systematic Reviews|October 7, 2011
Epidermal growth factor receptor blockers for the treatment of ovarian cancerKrishnayan Haldar, Kezia Gaitskell, Andrew Bryant, et al.
The Cochrane Database of Systematic Reviews|September 9, 2011
Angiogenesis inhibitors for the treatment of ovarian cancerKezia Gaitskell, Igor Martinek, Andrew Bryant, et al.
The Cochrane Database of Systematic Reviews|June 18, 2010
DNA-repair pathway inhibitors for the treatment of ovarian cancerIgor Martinek, Krishnayan Haldar, Kezia Gaitskell, et al.
BMJ Open|January 16, 2021
Randomised phase II trial of olaparib, chemotherapy or olaparib and cediranib in patients with platinum-resistant ovarian cancer (OCTOVA): a study protocolAnita Mansouri, Naomi McGregor, Rachel Dunn, et al.
Pageof 5